CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-18). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2876 · Search date 2026-08-18 · Methodology v0.7

Inhaled indacaterol-glycopyrronium LABA/LAMA combination,
does it really help with Fewer exacerbations than salmeterol-fluticasone in COPD with a prior exacerbation?

30-Second Summary
C
Evidence Grade C · 50 · Safety caution
LABA/LAMA lowered one-year exacerbation rates versus ICS/LABA within a narrow comparison
Both are prescription inhalers. Pneumonia occurred in 3.2% versus 4.8% in FLAME, while cardiovascular, anticholinergic, and inhaled-steroid considerations remain individual.
What the
research shows
The grade is C. FLAME's primary endpoint was 'the annual rate of all COPD exacerbations.' Rates were 3.59 versus 4.03 per patient-year, rate ratio 0.89 (95% CI 0.83 to 0.96), an absolute difference of -0.44 per patient-year, with P=0.003 for superiority after noninferiority was established.
What the
ads claim
An 11% rate reduction is not an 11% improvement in each person's symptoms. The absolute difference was 0.44 exacerbations per patient-year versus another active inhaler.
*

Useful facts when choosing a product

  • Indacaterol is a LABA and glycopyrronium a LAMA.
  • The comparator combined salmeterol LABA with inhaled fluticasone.
  • The 52-week trial was sponsored by Novartis.
Gap Measurement · Verdict 2876 · C 50
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The article defined mild events as 'worsening of symptoms for more than 2 consecutive days and not treated with systemic glucocorticoids or antibiotics,' moderate events as 'treated with systemic glucocorticoids, antibiotics, or both,' and severe events as 'requiring hospital admission or an emergency room visit that lasted more than 24 hours.' Thus the all-exacerbation primary endpoint mixed symptoms and treatment decisions rather than hospitalization alone. The declared threshold was: 'The noninferiority margin of 15% ... was based on a previous study.'

Axis 6 defect gates ① Defect name: noninferiority design. ② Listed item: noninferiority design. ③ Original evidence: 'randomized, double-blind, double-dummy, noninferiority trial' with a 1.15 rate-ratio margin. ④ Avoidable: yes; superiority could have been the primary hypothesis.

02

Why this is classified as C (50)

Superiority on a patient-centered exacerbation rate is accepted, but R1, I0, and one listed design defect - noninferiority design - yield C with 50 points.

Counterpoint. The result applies to patients with an exacerbation in the prior year; eosinophils and individual pneumonia risk still affect ICS selection.

Rejudgment record. Cross-check applied — Accepted superiority for exacerbation reduction while counting one noninferiority-design defect in a single manufacturer-funded trial

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI0Evidence comes only from manufacturer studies
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced annual rate of all COPD exacerbationsCSuperiority was shown: 3.59 versus 4.03, rate ratio 0.89.
Reduced moderate or severe exacerbationsCRates were 0.98 versus 1.19, rate ratio 0.83 (0.75 to 0.91).

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 152-week multicenter randomized double-blind double-dummy noninferiority and superiority trial1,682Sponsored by NovartisPrimary endpoint: annual rate of all COPD exacerbations3.59 versus 4.03 per year; rate ratio 0.89 (95% CI 0.83 to 0.96), absolute difference -0.44 per year, superiority P=0.003; also met the 1.15 noninferiority margin.Pivotal manufacturer-funded confirmatory trial
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-08-18).

Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222-2234. PMID: 27181606. DOI: 10.1056/NEJMoa1516385.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none

Cite this verdict

Benefit of Indacaterol-Glycopyrronium for Reducing Exacerbations in COPD with Prior Exacerbation Evidence Grade C card
[Chamgap] Benefit of Indacaterol-Glycopyrronium for Reducing Exacerbations in COPD with Prior Exacerbation — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/indacaterol-glycopyrronium-prior-exacerbation-copd-exacerbations/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.